MedTrace Logo

Histamine Pharmacogenetics in Children With Atopic Dermatitis

NCT00277433 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 751

Last updated 2017-03-20

No results posted yet for this study

Summary

The primary goal of the study is to investigate the impact of a common genetic polymorphism in a histamine detoxification enzyme that may well have a common role in regulating the expression of atopic dermatitis (AD) and other related atopic diseases in children.

Conditions

  • Dermatitis, Atopic

Interventions

OTHER

Buccal Swab

collection of buccal swab

Sponsors & Collaborators

  • American College of Clinical Pharmacy

    collaborator OTHER

  • PPRU

    collaborator UNKNOWN

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

    collaborator NIH

  • Virginia Commonwealth University

    lead OTHER

Principal Investigators

  • Mary Jayne Kennedy, Pharm D. · Virginia Commonwealth University

Eligibility

Min Age
6 Months
Max Age
5 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-06-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00277433 on ClinicalTrials.gov